Research Article

Bidirectional Interaction of Thyroid-Kidney Organs in Disease States

Fateme Shamekhi Amiri
National Tehran University of Medical Sciences, Faculty of Medicine, Imam Khomeini Hospital Complex, Tehran, Iran

Correspondence should be addressed to Fateme Shamekhi Amiri; fa.shamekhi@gmail.com

Received 11 June 2020; Revised 17 August 2020; Accepted 16 November 2020; Published 3 December 2020

Academic Editor: Jaime Uribarri

Copyright © 2020 Fateme Shamekhi Amiri. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Thyroid hormones play an important role in growth, development, and physiology of the kidney. The kidney plays a key role in the metabolism, degradation, and excretion of thyroid hormones and its metabolites. The aim of this study is to investigate the prevalence of disease states of thyroid-kidney organs and detecting the correlation between thyroid and kidney function abnormalities. Materials and Methods. In this retrospective study, a total of forty-five patients with thyroid and kidney dysfunction were investigated. Clinical features, laboratory data at initial presentation, management, and outcomes were collected. The paper has been written based on searching PubMed and Google Scholar to identify potentially relevant articles or abstracts. Median, percentage, mean ± standard deviation (SD), and the two-tailed t-test were used for statistical analyses. The correlation between variables was assessed by Pearson’s, Spearman’s correlation tests and regression analyses. Results. The mean ± SD of age of study patients was 48.2 ± 22.93 years (ranging from 1 to 90 years). There was no correlation between serum thyroid-stimulating hormone, free thyroxine levels with estimated glomerular filtration rate, and proteinuria. No association between antimicrosomal antibodies with estimated glomerular filtration rate was seen. Cardiovascular disease was the most common complication of overt hypothyroidism in kidney dysfunction patients. Conclusion. The present study showed more prevalence of primary hypothyroidism in comparison with other thyroid dysfunctions in patients with kidney dysfunction. Reduced mean values of thyroid function profiles after treatment suggest that this thyroid disease should be considered and ameliorated with thyroid hormone replacement therapy in patients with kidney disease.

1. Introduction

1.1. Description of Statement. Thyroid hormones are necessary for the growth and development of the kidney and for the maintenance of water and electrolyte homeostasis. On the other hand, kidneys are involved in the metabolism and elimination of thyroid hormones. Thyroid dysfunction is common in patients with chronic kidney disease [1]. Documentation of this association has come from large, well-documented clinical trials that found an inverse relationship between thyroid function (generally best assessed by measurement of serum thyrotropin levels) and estimated glomerular filtration rate [2]. Patients with chronic kidney disease exhibit a variety of endocrine disturbances, but the evidence of thyroid dysfunction exists only in laboratory parameters. Many of the patients are not associated with clinical signs and symptoms of disease. In other words, chronic kidney disease (CKD) is a well-known cause of nonthyroidal illness causing thyroid dysfunction, i.e., alteration in thyroid parameters in the absence of underlying thyroid disease [3].

1.2. Definition of the Thyroid Gland in Disease States. Normal values for thyroid-stimulating hormones (TSH) and free thyroid hormone levels (fT4 and fT3) are as follows:

(i) Normal thyroid function test (normal TSH in adults: 0.4–4 mIU/ml; fT4: 1–2.1 ng/dl; fT3: 2.4–5.9 pg/ml)

(ii) Hypothyroid state (high TSH; > 4 mIU/ml)

(iii) Hyperthyroid state (low TSH; < 0.4 mIU/ml)
2. Objectives

There are many uncertainties about thyroid abnormalities in kidney diseases and vice versa in literature review that can expressed as questions in this study. Furthermore, the aim of this study is to investigate the prevalence of disease states of thyroid-kidney organs and detecting the correlation between thyroid and kidney function abnormalities. The questions which are suggested are as follows:

2.1. How This Study Might Work. Thyroid functional disease is a risk factor for kidney disease, and some analyses suggest that even high-normal TSH levels may be a risk factor for kidney function. It has been suggested that hypothyroidism leads to kidney dysfunction via decreased cardiac output, altered intrarenal hemodynamics, reduced renin-angiotensin-aldosterone production and activation, and increased tubuloglomerular feedback in chloride channel and expression. Conversely, patients with CKD may be at higher risk for thyroid dysfunction via several pathways. Amelioration of risk factors prevents kidney disease progression, cardiovascular disease, and mortality. Therefore, more studies for evaluating the clinical and biochemical association are needed to better understand the causal implications of this disorder in kidney disease.

2.2. Why It Must Be Performed. Because clinical studies in patients with the dysfunctional thyroid state is low and not much data are available on how thyroid dysfunction influences renal function in human beings, this study has been planned. Furthermore, this study has been performed in these patients to investigate the alterations in kidney function in the dysfunctional thyroid state and to correlate these values with thyroid profiles of patients.

3. Methods

3.1. Criteria for Considering Studies for Review

3.1.1. Type of Studies. All case reports were obtained via electronic search in PubMed and Google Scholar databases.

3.1.2. Type of Participants. Patients with thyroid dysfunction and kidney disorders in all ages and both male and female were considered in this study. They were assessed for cardiovascular endpoints and mortality dependent on the available data.

3.1.3. Type of Outcome Measures. (1) Primary Outcomes. Development or progression of kidney disease, elevated serum creatinine (SCr), decrease of eGFR, and development or progression of thyroid dysfunction were primary endpoints in this study.

(2) Secondary Outcomes. Cardiovascular events, dyslipidemia, progression of subclinical hypothyroidism to primary hypothyroidism, and mortality were secondary endpoints in this study.

3.2. Search Methods for Identification of Studies

3.2.1. Electronic Search. The paper has been written based on advanced searching via PubMed and Google Scholar databases to identify articles that were published since inception to January 2020. The mentioned search included the following search terms: chronic kidney disease and thyroid dysfunction, thyroid and kidney disease, and thyroid and chronic kidney disease.

3.2.2. Searching Other Resources. The author reviewed references of all included articles and performed handsearching of related journals to identify the additional relevant studies.

3.3. Study Selection. The search strategy was used to obtain titles and abstracts of studies that might be relevant to the review. The titles and abstracts were screened by the author who discarded studies that were not applicable; however, studies and reviews that might include relevant data or information on studies were retained initially. The author independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria.
3.4. Data Collection and Analysis

3.4.1. Data Extraction and Management. Data extraction was carried out by the author, and studies reported in non-English language journals were to be translated before assessment. Where more than one publication of one study existed, reports were grouped together, and the publication with the most complete data was included.

3.5. Data Items. All patients of thyroid dysfunction with renal disorders and patients of renal dysfunction with thyroid disorders were investigated. Clinical features such as age, sex, different symptoms, and physical signs were extracted from this study. Furthermore, biochemical variables of TSH, fT4, fT3, Scr, eGFR, serum total cholesterol, serum triglyceride, hemoglobin (Hb), urine protein, antithyroid autoantibodies at initial presentation, imaging, management, and outcomes were collected.

3.6. Assessment of Risk of Bias and Quality in Included Articles. Case reports were analyzed using criteria developed by the Joanna Briggs Institute critical appraisal tool for case reports that have different assessment tools for each study design in question. The evaluation tool has 8 items for case reports.

3.7. Statistical Analysis. Data were entered in Microsoft Excel 2010 software. Categorical variables are recorded as frequency (N) and percentage (%). The continuous variables were determined as to whether they were normally distributed using the Kolmogorov–Smirnov test. Continuous variables with normal distribution are reported as mean ± standard deviation (SD). Nonparametric variables are expressed as median and interquartile range (Q1, Q3, and IQR). Comparisons between continuous variables with normally distributed (ND) data were assessed by the Wilcoxon-matched pairs test, and variables with nonnormally distributed (NND) data were assessed by the two-tailed one-sample t-test analysis. The correlation between continuous variables with normal distributed data was analyzed using product moment correlation (Pearson’s correlation coefficient test) (r) and with nonnormally distributed data assessed with Spearman’s rank correlation coefficient (r0). When one variable was nonnormally distributed (X) and another was normally distributed data (Y), regression analyses were used. Significance was assessed with the p value of <0.05.

4. Results

4.1. Description of Studies

4.1.1. Results of the Search and Study Selection. After searching electronic databases, the author identified 9831 records. After deduplicated articles, the author identified total of 9660 titles and abstracts. Then, 8993 articles were discarded due to unrelated subjects and other languages, and 667 articles were screened for consideration. With continuation of work, 55 full-text articles were considered eligible for further assessment. Of these, 40 published articles (45 case reports) were included, and fifteen studies were discarded due to nonoriginal investigation (Figure 1).

1. Included studies (criteria): forty published articles (45 case reports or participants) were considered for inclusion in this review.

4.1.2. Study Characteristics

Study design

Nonrandomized data of randomized trials were planned with systematic review design in this retrospective study.

Sample sizes

Sample sizes ranged from 45 to 59 patients in this study and fourteen patients were excluded from this study.

Setting

Most patients in this study were referred to single centers but several reports indicated multicenter follow-up.

Participants

All patients are included in this study if they had thyroid function test abnormality and kidney failure including acute kidney injury, chronic kidney disease, glomerular disease, nephrotic syndrome, and tubular disease.

4.1.3. Excluded Studies (Criteria). Patients were excluded from the study if they had renal or thyroid carcinoma in initial presentation.

4.2. Risk of Bias and Quality in the Included Studies. Assessment of risk of bias and quality in included articles performed using Joanna Briggs Institute critical appraisal tools for case reports. Based on these criteria, three patients presented with eight score (3/45, 66.6%), thirty-three patients with seven score (33/45, 73.3%), five patients with six score (5/45, 11.1%), and four patients with five score (4/45, 8.8%) (Supplementary Table S1).

4.3. Results of Case Studies

4.3.1. Patients' Characteristics. Among 55 full-text articles obtained in this research paper, 40 published articles were included in this study. These 40 articles included 45 case reports that examined 45 patients with thyroid and renal dysfunction for qualitative and quantitative syntheses [4–43]. Mean ± standard deviation (±SD) age of patients at the time of diagnosis was 48.2 ± 22.93 years (ranging from 1 to 90 years). Of these, twenty patients (21/45, 46.6%) were male and twenty-five patients (24/45, 53.3%) were female.
Distribution of age in male and female is described in Table 1 (Supplementary Table S2).

4.3.2. Patients’ Complaints. Patient’s history and physical examination are of paramount importance, especially in the setting of thyroid dysfunction in kidney disease and effect of kidney disease on thyroid disorders. The patients with primary hypothyroidism presented with muscle pain (9/30, 30%), as the most common symptom, fatigue and generalized edema (11.1%), weight gain and lethargy (8.8%), tiredness and generalized weakness (6.6%), and dyspnea and poor appetite (4.4%) in the present study. Patients with primary hyperthyroidism presented with fatigue and dyspnea (4.4%) and tiredness and increased appetite (2.2%). Patients with subclinical hypothyroidism presented with fatigue and generalized weakness (2.2%) and patients with subclinical hyperthyroidism presented with fatigue and muscle pain (2.2%) in this research. Patients with euthyroidism presented with dyspnea (2.2%) in the present study. Dry skin without edema has been seen in 12/30 (40%) patients as the most common sign in physical examination in the present study. Other signs in primary hypothyroidism include pallor and bilateral lower extremity edema (15.5%), periorbital edema (13.3%), overweight state (11.1%), enlarged palpable thyroid (8.8%), and inspiratory crackles (6.6%). Patients with primary hyperthyroidism presented with dry skin without edema (6.6%), enlarged palpable thyroid and inspiratory crackles (4.4%), and periorbital edema (2.2%). Patients with subclinical hypothyroidism presented with periorbital edema and bilateral lower extremity edema in 2.2%, and patients with subclinical hyperthyroidism presented with enlarged palpable thyroid and dry skin without edema in 2.2% cases (Supplementary Table S3).

4.3.3. Laboratory Data. The obtained laboratory data of patients in this study are classified as follows: overt hypothyroidism in thirty patients (30/45, 66.6%), overt hyperthyroidism (7/45, 15.5%), subclinical hyperthyroidism (3/45, 6.6%), and subclinical hypothyroidism, euthyroidism, and not determined (1/45, 2.2%). Common causes of thyroid dysfunction in the present study consisted Hashimoto’s thyroiditis in 6.6% of patients (3/45), and its other causes are described in Table 2. Three patients were in chronic kidney disease stage 0 (3/45, 6.6%), one patient in CKD stage II (1/45, 2.2%), four patients in CKD stage 3a (4/45, 8.8%), six patients in CKD stage 3b (6/45, 13.3%), four patients in CKD stage IV (4/45, 8.8%), and two patients in CKD stage 5T (2/45, 4.4%). The prevalence of anemia in patients of CKD with thyroid dysfunction was 31.11% (14/45), and the prevalence of anemia in primary hypothyroidism, primary hyperthyroidism, and euthyroidism has been reported in 71.4%, 21.4%, and 7.1%, respectively (Supplementary Table S4). There were hypokalemia and hyponatremia in four patients (4/45, 8.8%). Circulating antithyroid antibodies, specifically
antimicrosomal (AMA) and antithyroglobulin antibodies (ATA), are usually present in patients with autoimmune thyroid disease that the prevalence of them in the present study is given (Supplementary Table S5). Distribution and mean values of serum autoantibodies in different stages of the estimated glomerular filtration rate (eGFR) are given in Table 3. Metabolic syndrome definition according to National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) is the diagnosed co-occurrence of greater than or equal to three of five metabolic abnormalities: abdominal obesity (waist circumference, hyperglycemia, hypertension (HTN), and dyslipidemia in combination). Several studies have demonstrated a close association between metabolic syndrome and thyroid dysfunction. There was metabolic syndrome or syndrome X or insulin resistant syndrome in 2/30 (6.6%) of patients with overt hypothyroidism as the most common thyroid dysfunction in the present study. Prevalence of any risk factor of
metabolic syndrome has been described in the present study (Table 4) (Supplementary Table S6).

1) Primary Hypothyroidism. There was elevated TSH in thirty patients (30/45, 66.6%), and mean value for elevated TSH was 156.51 ± 252.82 mIU/ml. Serum fT4 values decreased in 26 patients (26/45, 57.7%), and mean value of decreased fT4 levels was 0.5 ± 0.5 ng/dl. There was decreased fT3 in nine patients (9/45, 20%), and mean ± SD of this hormone was 1.93 ± 1.54 pg/ml (Table 5). There was elevated serum creatine phosphokinase (CPK) in twelve patients (12/45, 26.7%) with a mean average of serum CPK of 18504.2 ± 31659.83 IU/l in primary hypothyroidism. There was no correlation between serum TSH and serum total cholesterol seen with $r = 0.13$ (p value of 0.69) (Figure 4). Moreover, there was no correlation between serum total cholesterol and fT4 with $r = -0.01$ (p value: NS). There was hypercreatininemia in twenty-two patients (22/30, 73.3%) with a mean value of 1.67 ± 0.27 mg/dl, and there was no correlation between serum TSH and fT4 levels and serum creatinine in this study. Furthermore, the impact of kidney dysfunction on thyroid function abnormalities has been assessed, and there was no correlation between serum creatinine and serum TSH and fT4 levels in accordance to statistical analyses (Figure 5). There was primary hypothyroidism in 2.2% of stage 2, 3a, 3b, and 4 of CKD, and there was also euthyroidism in 1/45 (2.2%) of stages of 4 of CKD.

Prevalence of low T4, T3, and elevated TSH in different stages of CKD has been shown in this study (Figure 6). Moreover, there was no association between serum TSH and fT4 levels with different stages of CKD (eGFR) and between
different stages of CKD with serum TSH and fT4 levels (Figures 7(a)–7(d)) (Supplementary Table S7). The correlation between elevated urine protein and serum TSH in this study was 0.85 (p value of 0.06), and really there was no significant relationship between proteinuria and primary hypothyroidism (Figures 8(a) and 8(b)). As previously mentioned, there was metabolic syndrome in one patient (1/45, 2.2%). Abdominal sonography including kidney sonography was abnormal in five patients (5/45, 11.1%), and eleven patients had normal results (11/45, 24.4%). Thyroid radioscintigraphy was performed in four patients and had abnormal results in two patients (2/45, 4.4%). Renal nuclear scan was performed in one patient and showed abnormal result (1/45, 2.2%) (Supplementary Table S9).

4.3.4. Imaging. In this study, chest X-ray showed abnormal and normal results in two patients (2/45, 4.4%). Thyroid sonography performed in 19 patients resulted abnormal findings in 12 patients (12/45, 26.6%). Of these patients, six patients showed normal results (6/45, 13.3%) and one patient had borderline result (1/45, 2.2%). Abdominal sonography including kidney sonography was abnormal in five patients (5/45, 11.1%), and eleven patients had normal results (11/45, 24.4%). Thyroid radioscintigraphy was performed in four patients and had abnormal results in two patients (2/45, 4.4%). Renal nuclear scan was performed in one patient and showed abnormal result (1/45, 2.2%) (Supplementary Table S9).

4.3.5. Treatment. In this study, the prevalence of used drugs included thyroid hormone replacement therapy (THRT) in 34 patients (34/45, 75.5%), steroids in ten patients (10/45, 22.2%), antithyroid drugs including methimazole (MMI) and propylthiouracil (PTU) in nine patients (9/45, 20%), saturated solution of potassium iodide (SSKI) in four patients (4/45, 8.8%), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in seven patients (7/45, 15.5%), beta-blockers, calcium channel blockers (CCBs), and kidney failure with replacement therapy (KRT) in six patients (6/45, 13.3%), and statins, diuretics, multivitamin/minerals, and immunosuppressive drugs in five patients (5/45, 11.1%). Before treatment, median and IQR values of TSH in hypothyroid states contained 100 and 170 mIU/ml (Q3–Q1: 211.2–40.5), respectively. Median and IQR values of serum TSH after THRT resulted in 10.8 and 31.16 mIU/ml (Q3–Q1: 211.2–40.5), respectively. There was a statistical significance for serum TSH levels before and after treatment with THRT (p value of 0.003; ω value = 0) (Table 6) (Supplementary Table S10).

4.3.6. Follow-Up. In this study, serum TSH has been assessed in nineteen patients (19/45, 42.2%) after treatment. Median time of blood sampling for initial normal serum TSH after drug treatment in these patients has been calculated 4 months with an IQR of 5 months (Q3–Q1 = 6–1), minimum (Min) of 0.5 mo, maximum (Max) of 24 mo, midrange of 23.5 mo, and mean of 5.96 mo. Outcomes of thyroid dysfunction in renal disease include cardiovascular disease, dyslipidemia, progression of subclinical hypothyroidism to primary hypothyroidism, and death (Table 7) (Figure 9) (Supplementary Table S11).
| Age (years) | Male (21/45, 46.6%) | Female (24/45, 53.3%) |
|------------|---------------------|-----------------------|
|            |  Primary hypothyroidism | Subclinical hypothyroidism | Primary hyperthyroidism | Subclinical hyperthyroidism | Euthyroidism | Primary hypothyroidism | Subclinical hypothyroidism | Primary hyperthyroidism | Subclinical hyperthyroidism | Euthyroidism |
| 0–19       | 2/15 (13.3%) | 0 | 0/7 | — | — | 2/15 (13.3%) | 1/7 (14.2%) | — | — | — | — |
| 20–39      | 2/15 (13.3%) | 0 | 1/7 (14.2%) | — | — | 2/15 (13.3%) | 2/7 (28.5%) | — | — | — | 1/1 |
| 40–59      | 7/15 (46.6%) | 0 | 1/7 (14.2%) | — | 1/2 | 5/15 (33.3%) | 1/7 (14.2%) | — | — | — | — |
| 60–79      | 2/15 (13.3%) | 0 | 1/7 (14.2%) | 1/3 (33.3%) | — | 5/15 (33.3%) | 0/7 | 1/3 (33.3%) | — | — | — |
| ≥80        | 2/15 (13.3%) | 0 | 0/7 | — | — | 1/15 (6.6%) | 0/7 | 1/3 (33.3%) | — | — | — |
| — Total: 15/30 (50%) | — | Total: 3/7 (42.8%) | Total: 1/2 (50%) | Total: 15/30 (50%) | Total: 4/7 (57.1%) | Total: 2/3 (66.6%) | Total: 1/1 | Total: 1/2 (50%) | — | — |
| — Mean ± SD of age: 48.13 ± 24.53 | — | Mean ± SD for age: 54 ± 15.5 | — | — | Mean ± SD for age: 49.8 ± 22.57 | Mean ± SD for age: 32 ± 16.44 | Mean ± SD for age: 76 ± 6 | — | — |

SD, standard deviation.
Table 2: Causes of thyroid dysfunction in kidney failure.

| Causes of thyroid dysfunction | Frequency (percentage) |
|------------------------------|------------------------|
| Hashimoto’s thyroiditis      | 3/45 (6.6%)            |
| Rhabdomyolysis               | 2/45 (4.4%)            |
| Amyloidosis                  | 1/45 (2.2%)            |
| Chronic thyroiditis          | 1/45 (2.2%)            |
| Simvastatin usage            | 1/45 (2.2%)            |
| ADPKD                        | 1/45 (2.2%)            |
| Idiopathic                   | 1/45 (2.2%)            |
| Iodine-induced               | 1/45 (2.2%)            |
| Non-autoimmune               | 1/45 (2.2%)            |
| Multinodular goiter          | 1/45 (2.2%)            |

ADPKD, autosomal dominant polycystic kidney disease.

Table 3: Distribution and mean values of thyroid autoantibodies in thyroid-kidney dysfunction.

| AutoAbs                  | eGFR < 15 | eGFR 15–29 | eGFR 30–44 | eGFR 45–59 | eGFR 60–89 | eGFR ≥ 90 |
|--------------------------|-----------|------------|------------|------------|------------|-----------|
| TG, thyroglobulin        | —         | —          | —          | —          | —          | —         |
| Anti-TG Ab (anti-TPO Ab) | —         | —          | —          | —          | —          | —         |
| Anti-TSH R blocking Ab   | —         | —          | —          | —          | —          | —         |
| (TBA)                    | —         | —          | —          | —          | —          | —         |
| Thyrotropin-binding inhibitory Ig (TBII) | —         | —          | —          | —          | —          | —         |
| Thyroid-stimulating Abs (TSI) | —         | —          | —          | —          | —          | —         |
| Na+/I-symporter Ab (NIS)  | —         | —          | —          | —          | —          | —         |
| HLA-DR3 gene             | —         | —          | —          | —          | —          | —         |
| CTLA4 gene               | —         | —          | —          | —          | —          | —         |

AMA, antimicrosomal antibody (former antithyroid peroxidase antibody); anti-TSH R Abs, antithyrotropin receptor antibodies; CTLA 4 gene, T cell regulatory gene; eGFR, estimated glomerular filtration rate; HLA-DR3, human leukocyte antibody-DR3; IU/ml, international unit per milliliter; NIS, sodium/iodide symporter antibodies; SCH, subclinical hyperthyroidism; SD, standard deviation; TG, thyroglobulin; TSI, thyroid-stimulating immunoglobulin ≤16% inhibition in adults and children, 16–100% inhibition in grave’s disease. TBII ≤1.75 IU/l is considered normal.

Table 4: Prevalence of metabolic syndrome or any risk factors of metabolic syndrome in thyroid dysfunction.

| Disease             | Risk factor          |
|---------------------|----------------------|
| HTN                 | T2DM                 |
| Primary hypothyroidism | 13/30 (43.3%) | 9/30 (30%) |
| Primary hyperthyroidism | 3/7 (42.8%) | 1/7 (14.2%) |
| SCH                 | 1/3 (33.3%)          |
| SCH0                | 1/1                  |
| Euthyroidism        | 1/2 (50%)            |

HDL, high-density lipoprotein; HTG, hypertriglyceridemia; HTN, hypertension; MS, metabolic syndrome; SCH, subclinical hypothyroidism; SCH0, subclinical hypothyroidism; T2DM, type 2 diabetes mellitus; WS, waist circumference.

Table 5: Prevalence of mean ± SD values of thyroid dysfunction in kidney diseases.

| Disease                          | BT | TSH | ft4 | ft3 |
|----------------------------------|----|-----|-----|-----|
| Primary hypothyroidism           |    | 156.51 ± 252.82 mIU/ml | 0.01 ± 0.004 mIU/ml | 6.28 ± 4.66 ng/dl |
| Primary hyperthyroidism          |    | 11.89 mIU/ml | — | — |
| Subclinical hypothyroidism       |    | 0.03 ± 0.02 mIU/ml | — | — |
| Subclinical hyperthyroidism      |    | 1.44 ± 0.64 mIU/ml | — | — |
| Euthyroidism                     |    | 5.16 ± 0.16 ng/dl | — | — |
|                                  |    | 2.5 ± 0.33 pg/ml | — | — |

BT, biochemical test; ft3, free triiodothyronine; ft4, free thyroxin; TSH, thyroid-stimulating hormone.
Figure 7: Correlation between serum TSH and fT4 levels with different stages of CKD. a, b. Impact of abnormal TSH and fT4 levels on different stages of CKD in primary hypothyroidism. c, d. Impact of kidney dysfunction on serum TSH and fT4 levels in primary hypothyroidism. CKD, chronic kidney disease; fT4, free thyroxin; TSH, thyroid-stimulating hormone.

Figure 8: Correlation between proteinuria and serum TSH and fT4 levels in primary hypothyroidism in the current study. Impact of proteinuria on thyroid function tests has been shown accurately. fT4, free thyroxin; TSH, thyroid-stimulating hormone.
| Biochemical test | Primary hypothyroidism (mean ± SD, median) | Subclinical hypothyroidism (mean ± SD) | Primary hyperthyroidism (mean ± SD) | Subclinical hyperthyroidism (mean ± SD) | Euthyroidism (mean ± SD) |
|------------------|----------------------------------------|--------------------------------------|-------------------------------------|----------------------------------------|------------------------|
|                  | Before Tx | After Tx | Before Tx | After Tx | Before Tx | After Tx | Before Tx | After Tx | Before Tx | After Tx | Before Tx | After Tx |
| TSH (NND)        |           |          |           |          |           |          |           |          |           |          |           |          |
| N=11 244.88±392.62 median: 100; Q1: 40.5; Q3: 211.2; IQR: 170.7 | N=11 24.28±29.55 median: 10.8; Q1: 2.44; Q3:33.6; IQR: 31.16 | Result 1— p value: 0.003 (SS, z value: −2.93, w value: 0), result 2: SS — — — 1.44 ± 0.64 |
| fT4 (ND)         | N=10 0.44±0.31 | N=10 1.14±0.41 | | | |
| fT3 (ND)         | N=3 1.29±0.68 | N=3 2.43±0.82 | | | |
| Total CPK (ND)   | N=5 18504.2±31659.8 | N=5 624.4±653.44 | p value: 1 (NS) | | |
| Total cholesterol (ND) | N=3 352.6±20.19 | N=3 19±18.47 | | | |
| Serum creatinine (ND) | N=11 1.67±0.27 | N=11 1.45±0.49 | p value: 0.957 (NS); p value: 0.981(NS) | | |

CPK, creatine phosphokinase; fT3, free triiodothyronine; fT4, free thyroxin; ID, insufficient data; IQR, interquartile range; N, number; ND, normally distributed; NDD, nonnormally distributed; NS, not significant; Q1, first quartile; Q3, third quartile; SD, standard deviation; SS, statistical significant; TSH, thyroid stimulating hormone; Tx, treatment.
5. Discussion

Thyroid and kidney functions are known to interact, and thyroid dysfunction is known to cause significant changes in kidney function, especially to affect GFR. Thyroid hormones are involved in the growth, development, and physiology of the kidney. Decreased or elevated thyroid hormones affect glomerular filtration rate, renal blood flow, tubular function, water-electrolyte balance, and kidney structure [44]. Thyroidal functional disease and in particular hypothyroidism is highly prevalent among CKD and kidney failure patients. In the present study, 25/45 (55.5%) patients were female and 20/45 (20%) were male and the obtained results were in contrast with the study by Petimani and Adake that 77.7% of patients (35/45) were male and 22.2% of them (10/45) were female [45]. These results were in agreement with the study by Rashead and Aryee et al. [46, 47]. Low thyroid hormone levels (i.e., triiodothyronine) have been associated with adverse cardiovascular sequelae in CKD and kidney failure, but these metrics are confounded by malnutrition, inflammation, and comorbid states and hence may signify nonthyroidal illness (i.e., thyroid functional test derangements associated with underlying ill health in the absence of thyroid pathology). It has hypothesized that hypothyroidism is an underrecognized, modifiable risk factor for the enormous burden of cardiovascular disease and death in CKD and kidney failure [48]. CKD has been known to affect the pituitary-thyroid axis and the peripheral metabolism of thyroid hormones. One of the most important links between thyroid disorders and CKD is uremia [49]. The author identified a significant association between thyroid dysfunction (both hypothyroidism and hyperthyroidism) and high mortality in patients with stage 3 CKD with an increased risk of death (17%–27% above the risk). These results were identified in euthyroid patients with CKD over a median follow-up period of 5.5 years [2]. Thyroid functions have subtle clinical features associated with some forms of thyroid dysfunction. The clinicians must decide which test is best suitting to diagnose or exclude disorder. It is emphasized that a single thyroid function test (TFT) is not absolute in diagnostic accuracy, and thus, it must be a careful selection of such tests, so that their combination can give comprehensive data that would enhance the diagnostic accuracy. In the study by Rasheed and Hamid, there was a significant difference between normal and abnormal values of creatinine, while there was a highly significant difference ($P < 0.001$) between normal and abnormal values of TSH, T3, and T4 [46]. Prevalence of fT4 and fT3 levels in our patients were 57.7% and 17.7%, respectively, in contrast with the study by Vivek Paul Benjamin et al. that these values were 68% and 24% in serum TSH levels of $>10$ mIU/ml, respectively [50]. Furthermore, the study by Fan et al. revealed the high prevalence of low T3 syndrome in nondialysis-dependent chronic kidney disease (NDD-CKD) patients even in early stages [51]. As we know, pallor is the first sign of hypothyroidism in these patients, while it occurs in greater than 20% of patients (as a second sign of primary hypothyroidism) in our patients. As previously known, over 40% of patients with CKD are anemic. So, suspicion of a relationship between thyroid dysfunction and anemia with CKD should be considered. In our study, there was anemia in 31.11% of patients, and 71.4% of anemic patients with CKD were presented with elevated TSH. Moreover, 57.1% and 35.7% of patients with anemia and CKD had low fT4 and fT3 levels, respectively. Conversely, the prevalence of anemia in low T3 syndrome and CKD was reported as 84.2% in Fan et al.’ study. This study was performed with

| Disease                      | CVD by TTE | Dyslipidemia (TC and TG) | Mortality | Progression to overt hypothyroidism |
|------------------------------|------------|--------------------------|-----------|-----------------------------------|
| Primary hypothyroidism       | 6/45 (13.3%) | 11/45 (24.4%) and 5/45 (11.1%) | 1/45 (2.2%) | —                                 |
| Subclinical hypothyroidism   | —          | 1/45 (2.2%) and 1/45 (2.2%) | —         | 0                                 |
| Primary hyperthyroidism      | —          | —                        | —         | —                                 |
| Subclinical hyperthyroidism  | 1/45 (2.2%) | —                        | —         | —                                 |
| Euthyroidism                 | —          | —                        | —         | —                                 |

CVD, cardiovascular disease; TC, total cholesterol; TG, triglyceride; TTE, transthoracic echocardiography.

![Figure 9: Distribution of various outcomes in thyroid-kidney disease.](image-url)
consideration that there was a positive correlation between serum total protein, prealbumin, and albumin levels and serum total triiodothyronine levels (TT3) levels according to the study by Fan et al. and a positive correlation between serum protein and albumin with serum TSH levels according to the study by Arora et al. [52], but it resulted in different findings. In this study, there was no relationship between serum TSH and fT4 levels and proteinuria, and that result was consistent with the result of the study by Gilles et al. [53], while in the study by Du et al., there was a positive correlation between serum total thyroxin levels (TT4) and fT4 levels with albuminuria, but albuminuria was not associated with TT3, fT3, and TSH [54]. Another study by Sridharan et al. documented a positive relationship between fT4 and fT3 levels with microalbuminuria [55]. The present study revealed no correlation between eGFR and serum fT4 and TSH levels that was in agreement with the study by Vivek Paul Benjamin et al. Another study by Khatiwada et al. concluded that stage 4 and stage 5 CKD patients had significantly higher risk of having thyroid dysfunction in comparison to stage 3 CKD [56]. While our study showed a higher prevalence of elevated TSH and low fT3 levels in stage 3b CKD and higher prevalence of low fT4 levels in stage IV CKD. Another keypoint that should be noticed in this study is attributed to the mortality rate of 2.2% in one patient with primary hypothyroidism, and the etiology of the unexpected death could not be established because the relatives refused a pathological postmortem biopsy. The serum fT4 level was within the normal range, although the TSH level was still high but lower than initial presentation, and serum creatinine was 209 μmol/l (laboratory tests at the time of death). Hypothyroidism may induce de novo AKI or CKD progression due to the hypodynamic circulatory state that was created by thyroid hormone deficiency. Moreover, paralytic ileus due to autonomic neuropathy (due to hypokalemia) can be caused by urinary retention. Therefore, clinicians must be alert from rare manifestations or complications of hypothyroidism such as acute kidney injury and paralytic ileus due to untreated hypothyroidism as if mostly thyroxine deficiency may be missed and treatment can reverse the complications [34]. Consistent with this finding, the study by Rhee et al. suggested that hypothyroidism is associated with higher mortality in dialysis patients which may be ameliorated by THRT [57]. There are several reports suggesting that metabolic syndrome is closely associated with thyroid dysfunction due to the impact of thyroid hormones on lipid metabolism, glucose, blood pressure, and cardiovascular dysfunction. This study detected metabolic syndrome in 2/30 (6.6%) patients with primary hypothyroidism as the most common thyroid disease in this study. Conversely, thyroid dysfunction and hypothyroidism were seen in 28% and 69/432 (16%) of patients with metabolic syndrome in the study by Deshmukh et al., respectively. The predominance of hypothyroidism (primary and subclinical: 25.7%) suggests that metabolic syndrome could also be a consequence or sequela of various stages of hypothyroidism during the natural course of disease [58]. Moreover, Wolffenbuttel et al. in a cohort study concluded that higher plasma levels of fT3 were associated with several components of metabolic syndrome when corrected for possible confounding factors. Only in men, lower fT4 levels were related to metabolic syndrome. There was a 50–80% increased risk of having metabolic syndrome compared to lowest quartile of the highest fT3 and fT3/fT4 ratio quartiles [59]. To end, there were some limitations in this study. First, insufficient data were seen in some of case reports. Second, there were low case numbers for the different clinical categories of thyroid dysfunction in patients with kidney dysfunction, e.g., thirty patients with primary hypothyroidism were included in this study.

6. Conclusions

The interplay between the thyroid and kidney in each other’s function is known for many years. Thyroid function affects renal physiology and development, whereas kidney failure could result in thyroid dysfunction. The present study demonstrated that the prevalence of primary hypothyroidism was high in patients with kidney dysfunction. Prevalence of hypothyroidism, elevated CPK, hypercholesterolemia, and raised serum creatinine levels was high in stage 3b CKD patients. Moreover, prevalence of elevated TSH and low fT3 levels was high in stage 3b CKD, and low fT4 levels was higher in stage IV CKD. There was no correlation between thyroid function tests (serum TSH and serum thyroxine levels) and decreased eGFR, hypercholesterolemia, and proteinuria in the present study. The findings of the present study have a lot of clinical relevance, since a multisystem approach to treat patients with diseases affecting either of these organs (the thyroid or kidney) would prove vitality to avoid missing subtle but clinically relevant abnormalities.

Abbreviations

ACEIs: Angiotensin-converting enzyme inhibitors
ADQI: Acute disease quality initiative
AMA: Antimicrosomal antibodies
ARBs: Angiotensin-receptor blockers
ATA: Antithyroglobulin antibodies
CCBs: Calcium channel blockers
CPK: Creatine phosphokinase
eGFR: Estimated glomerular filtration rate
ESRD: End-stage renal disease
MMI: Methimazole
NCEP-ATP: National Cholesterol Education Program III:
NDD-CKD: Nondialysis-dependent chronic kidney disease
PTU: Propylthiouracil
SD: Standard deviation
THRT: Thyroid hormone replacement therapy
TSH: Thyroid-stimulating hormone.

Data Availability

The datasets used to support the findings of this study are included in additional supporting files.
Additional Points

Highlights. High prevalence of primary hypothyroidism in patients with kidney dysfunction. High prevalence of elevated CPK, hypercholesterolemia, and raised serum creatinine levels in stage 3b CKD patients. High prevalence of elevated TSH and low FT3 levels in stage 3b CKD and low FT4 levels in stage IV CKD. No correlation between thyroid function tests and decreased eGFR, hypercholesterolemia, and proteinuria.

Conflicts of Interest

The author declares that there are no conflicts of interest.

Authors’ Contributions

The author contributed to study concept, design, data collection, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing, and manuscript review, and he is the guarantor.

Acknowledgments

The author thanks the National University of Tehran Medical Sciences, College of Medicine and Imam Khomeini Hospital Complex.

Supplementary Materials

Table S1. JBI critical appraisal tool for case reports in included articles. Tables S2(a)–S2(c). Raw data of age, sex, and laboratory parameters in thyroid-kidney dysfunction. Table S3. Raw data of symptoms and signs. Table S4. Prevalence of changes of TSH, FT4, and FT3 in CKD patients with anemia. Table S5. Distribution of positive thyroid autoantibodies in the current study. Table S6. Raw data of metabolic syndrome and its components in the present study. Table S7. Correlation between eGFR and serum TSH and FT4 in disease states. Tables S8(a)–S8(d). Raw data of laboratory findings in the present study. Tables S9(a)–S9(b). Raw data and frequency of imaging modalities in clinical studies. Tables S10(a)–S10(c). Thyroid function tests, serum creatinine, creatine phosphokinase, and total cholesterol before following treatment and follow-up in enrolled patients. Tables S11(a)–S11(c). Raw data and statistical analyses of laboratory parameters following thyroid hormone replacement therapy in hypothyroidism. (Supplementary Materials)

References

[1] P. Iglesias and J. J. Diez, “Thyroid dysfunction and kidney disease,” European Journal of Endocrinology, vol. 160, no. 4, pp. 503–515, 2009.
[2] M. N. Stan and M. T. Drake, “Failing kidneys and thyroid dysfunction—an undesirable synergy,” Mayo Clinic Proceedings, vol. 93, no. 5, pp. 555–557, 2018.
[3] G. Basu and A. Mohapatra, “Interactions between thyroid disorders and kidney disease,” Indian Journal of Endocrinology and Metabolism, vol. 16, no. 2, pp. 204–213, 2012.
[4] T. Dragovic, “Reversal deterioration of renal function accompanied with primary hypothyroidism,” Vojnosanitetski Pregled, vol. 69, no. 2, pp. 205–208, 2012.
[5] M. Suzuki, J. Yoshimura Noh, K. Sugino, and K. Ito, "Outpatient," Internal Medicine, vol. 55, pp. 3309–3313, 2016.
[6] S. Soh, O. Akı, O. Manabu, K. Nomiymasa et al., “A case of minimal change nephrotic syndrome with hypothyroidism deterioration,” CEN Case Reports, vol. 5, pp. 95–98, 2016.
[7] E. L. Hardegree and R. C. Albright, “Amiodarone-induced hypothyroidism presenting as cardiorenal syndrome,” Case Reports in Cardiology, vol. 2012, Article ID 161450, 3 pages, 2012.
[8] J. Shaho, I. Veerappan, A. Abraham et al., “Hypothyroidism complicating Nephropathy in a diabetes patient,” Case Reports in Endocrinology, vol. 2012, Article ID 237563, 4 pages, 2012.
[9] E. Tatar, T. Isikyakar, K. P. Yeniari et al., “Hypothyroidisms induced severe rhabdomyolysis in a hemodialysis patient,” Case Reports in Medicine, vol. 2014, Article ID 501890, 4 pages, 2014.
[10] E. A. Mc Aninch and V. S. Lagari, “Acute-on-chronic kidney injury in thyroid hormone withdrawal: a case with possible implications for radioactive planning,” Case Reports in Endocrinology, vol. 2015, Article ID 932372, 3 pages, 2015.
[11] K. Lithgow and C. Symonds, “Severe thyrotoxicosis secondary to povidone-iodine from peritoneal dialysis,” Case Reports in Endocrinology, vol. 2017, Article ID 2683120, 4 pages, 2017.
[12] A. Bautista, J. E. De Leon Duya, and M. A. S. Sandoval, “Salt-losing nephropathy in hypothyroidism,” BMJ Case Reports, vol. 2014, Article ID 203895, 4 pages, 2014.
[13] M. L. Patel and R. Uniyal, “Two unusual cases of hypothyroidism with renal dysfunction,” BMJ Case Reports, vol. 2011, Article ID 3707, 2 pages, 2011.
[14] G. C. Ezeji, T. Inoue, G. Bahtiyar et al., “Hallucinations associated with milgitol use in a patient with chronic kidney disease and hypothyroidism,” BMJ Case Reports, vol. 2015, Article ID 207345, 7 pages, 2015.
[15] S. Bell, J. A. Sosa, A. D. V. Jaen et al., “Thyroid lipomatosis in a 36-year-old patient with rheumatoid arthritis and a kidney transplant,” Endocrinology Diabetes and Metabolism Case Reports, vol. 2016, Article ID 160007, 6 pages, 2016.
[16] P. M. S. Change and Y. Y. Ng, “Amiodarone-induced hypothyroidism with EPO-resistant anemia in a patient with chronic renal failure,” Journal of the Chinese Medical Association, vol. 71, no. 11, pp. 576–578, 2008.
[17] J. T. Fang and C. C. Huang, “Distal renal tubular acidosis associated with non-autoimmune hypothyroidism,” Nephrology Dialysis Transplantation, vol. 11, pp. 1146–1147, 1996.
[18] G. C. P. Ledo Silva, J. B. Cameiro, C. C. Tardelli et al., “Kidney failure in the elderly due to hypothyroidism: a case report,” Sao Paulo Medical Journal, vol. 126, no. 5, pp. 291–293, 2008.
[19] E. So and R. Arakaki, “Toxic multinodular goiter in a patient with end-stage renal disease and hemodialysis,” Hawai’i Journal of Medicine & Public Health, vol. 73, no. 7, pp. 217–220, 2014.
[20] S. Vikrant, S. Chander, S. Kumar et al., “Hypothyroidism presenting as reversible renal impairment: an interesting case report,” Renal Failure, vol. 35, no. 9, pp. 1292–1294, 2013.
[21] Y. Sasaki, Y. Shimizu, J. Nakata et al., “Thyroid storm masked by hemodialysis and glucocorticoid therapy in a patient with
rheumatoid arthritis," *Case Reports in Nephrology and Urology*, vol. 2, no. 1, pp. 6–10, 2012.

[22] O. Uemura, N. Iwata, T. Nagal et al., "Influence of thyroid function on glomerular filtration and other estimates of kidney function in two pediatric patients," *CEN Case Reports*, vol. 7, no. 1, pp. 169–173, 2018.

[23] A. A. De Sousa, H. S. Kronit, F. De Assis Rocha Neves et al., "Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism," *Arquivos Brasileiros de Endocrinologia & Metabologia*, vol. 53, no. 3, pp. 383–386, 2009.

[24] M. Jabari and H. Alshehri, "Clinical relevance of hypothyroidism screening in a child with an unexplained elevated serum creatinine," *Imam Journal of Applied Sciences*, vol. 1, no. 1, pp. 39–41, 2016.

[25] Z. Li and Y. Wang, "Chronic kidney disease caused by hyperthyroidism," *Journal of Integrative Nephrology Andrology*, vol. 2, no. 3, pp. 93–95, 2015.

[26] B. Joshi, D. Jones, A. Rochford et al., "Hypothyroidism and associated acute renal failure," *Journal of the Royal Society of Medicine*, vol. 102, pp. 199–200, 2009.

[27] M. S. Petimani and P. Adake, "Estimation of thyroid function tests in patients with chronic kidney disease: a cross sectional observational study," *Journal of Advanced Research in Biochemistry and Pharmacology*, vol. 1, no. 182, pp. 15–19, 2018.

[28] T. Iwaoka, T. Umeda, M. Nakayama et al., "A case of membranous nephropathy associated with thyroid antigens," *Japanese Journal of Medicine*, vol. 21, no. 1, pp. 29–34, 1982.

[29] M. Karawajczyk, M. Ramkint, and A. Larsson, "Reduced cystatin-estimated GFR and increased creatinine-estimated GFR in comparison with iohexole-estimated GFR in a hyperthyroid patient: a case report," *Japanese Journal of Medicine Case Reports*, vol. 2, no. 66, pp. 1–3, 2008.

[30] J. Choy, J. Yaxley, and W. Yaxley, "A rare case of renal impairment caused by primary hypothyroidism," *Korean Journal of Family Medicine*, vol. 39, no. 3, pp. 204–206, 2018.

[31] C. Baek, K. Ae Lee, T. S. Park et al., "Graves’ disease presenting with acute renal infarction," *Korean Journal of Internal Medicine*, vol. 29, pp. 825–826, 2016.

[32] J. C. Baena, J. Padilla, and J. Guzman, "Thyroid storm associated with multiorganic dysfunction," *Medicina*, vol. 77, no. 4, pp. 337–340, 2017.

[33] P. D. M. De Menezes Neves, R. A. Bardi, A. L. Balbi et al., "Hypothyroidism and acute kidney injury: an unusual association," *BMJ Case Reports*, vol. 2013, Article ID 200585, 3 pages, 2013.

[34] C. Rodrigo, C. S. Gamakaranage, D. S. Epa et al., "Hypothyroidism causing paralytic ileus and acute kidney injury case report," *Thyroid Research*, vol. 4, no. 7, pp. 1–4, 2011.

[35] F. A. Qari, "Severe rhabdomyolysis and acute renal failure secondary to use of simvastatin in undiagnosed hypothyroidism," *Saudi Journal of Kidney Diseases and Transplantation*, vol. 20, no. 1, pp. 127–129, 2009.

[36] N. Sekine, M. Yamamoto, M. Michikawa et al., "Rhabdomyolysis and acute renal failure in a patient with hypothyroidism," *Internal Medicine*, vol. 32, no. 3, pp. 269–271, 1993.

[37] A. Alejmi and J. A. Sayer, "Multiple thyroid cysts as an extra-renal manifestation of ADPKD," *NDT Plus*, vol. 1, no. 4, pp. 266–268, 2008.

[38] A. Connor and J. E. Taylor, "Renal impairment resulting from hypothyroidism," *NDT Plus*, vol. 1, no. 6, pp. 440–441, 2008.

[39] M. Asim and M. El Esnavi, "Renal dysfunction manifesting in subclinical hypothyroidism-a possible role for thyroxin," *NDT Plus*, vol. 3, no. 3, pp. 282–284, 2010.

[40] T. Sanai, K. Okamura, K. Sato et al., "Masked hyperthyroidism in a hemodialysis patient successfully treated by potassium iodide," *Clinical Kidney Journal*, vol. 5, no. 1, pp. 70–72, 2012.

[41] A. S. Lopez and M. V. M. Ferrer, "Iatrogenic thyroid dysfunction in peritoneal dialysis," *Nefrologia*, vol. 28, no. 4, p. 467, 2008.

[42] M. Alfaro, C. Simao, T. Campos et al., "Hypothyroidism and terminal renal failure in the neonatal period," *Acta Medica Portuguesa*, vol. 21, no. 4, pp. 379–382, 2008.

[43] B. Barman, F. K. Bhattacharya, V. Raphael et al., "Hypothyroidism with IgA nephropathy: a rare association," *NEGIHMS Journal of Medical and Health Sciences*, vol. 6, no. 1, pp. 60–62, 2014.

[44] M. Kimmel, N. Braun, and M. D. Alschler, "Influence of thyroid function on different kidney function tests," *Kidney & Blood Pressure Research*, vol. 35, no. 1, pp. 9–17, 2012.

[45] M. Petimani and P. Adake, "Estimation of thyroid function tests in patients with chronic kidney disease: a cross sectional observational study," *Journal of Advanced Research in Biochemistry and Pharmacology*, vol. 1, no. 182, pp. 15–19, 2018.

[46] Q. A. Rashad and D. M. Hamid, "The effect of thyroid hormone on some biochemical factors of kidney," *International Journal of Advanced Research*, vol. 3, no. 7, pp. 290–297, 2015.

[47] N. A. Aryee, E. A. Tagoe, V. Anomah et al., "Thyroid hormone status in Ghanian patients with kidney disease," *The Pan African Medical Journal*, vol. 29, pp. 137–142, 2018.

[48] C. M. Rhee, G. A. Brent, C. P. Kovesdy et al., "Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients," *Nephrology Dialysis Transplantation*, vol. 30, no. 5, pp. 724–737, 2014.

[49] M. Mohamedali, S. R. Maddika, A. Vyas, V. Iyer, and P. Cheriyath, "Thyroid disorders and chronic kidney disease," *International Journal of Nephrology*, vol. 2014, Article ID 520281, 6 pages, 2014.

[50] V. Vivek Paul Benjamin, S. Kirubakaran, K. Elavarasan, and S. Natarajan, "A prospective study on the evaluation of thyroid function status in patients with chronic kidney disease," *Journal of Medical Science and Clinical Research*, vol. 5, no. 9, pp. 28007–28013, 2017.

[51] J. Fan, P. Yan, Y. Wang, B. Shen, F. Ding, and Y. Liu, "Prevalence and clinical significance of low T3 syndrome in non-dialysis patients with chronic kidney disease," *Medical Science Monitor*, vol. 22, pp. 1171–1179, 2016.

[52] S. Arora, R. Chawla, D. Tayal, V. K. Gupta, J. S. Sohi, and V. Mallika, "Biochemicals of liver and kidney function are influenced by thyroid function-a case-controlled follow up study in Indian hypothyroid subjects," *Indian Journal of Clinical Biochemistry*, vol. 24, no. 4, pp. 370–374, 2009.

[53] R. Giles, M. den Heijer, A. H. Ross, F. C. G. J. Sweep, A. R. M. M. Hermus, and J. F. M. Wetzel, "Thyroid function in patients with proteinuria," *Netherlands Journal of Medicine*, vol. 66, no. 11, pp. 483–485, 2008.

[54] X. Du, B. Pan, W. Li et al., "Albuminuria is an independent risk factor of T4 elevation in chronic kidney disease," *Scientific Reports*, vol. 7, pp. 1–7, 2017.

[55] S. Sridharan, S. T. Sengottayalan, G. Gurunamasivayam, and P. Kannan, "Prevalence of microalbuminuria in patients with thyroid dysfunction," *Journal of Medical Science and Clinical Research*, vol. 5, no. 6, pp. 23957–23971, 2017.

[56] S. Khatiwada, B. Gelal, N. Baral, and M. Lamsal, "Association between iron status and thyroid function in Nepalese children," *Thyroid Research*, vol. 9, no. 2, pp. 1–7, 2016.
[57] C. M. Rhee, E. K. Alexander, I. Bhan, and S. M. Brunelli, “Hypothyroidism and mortality among dialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 4, pp. 593–601, 2013.

[58] V. Deshmukh, F. Farishta, and M. Bohle, “Thyroid dysfunction in patients with metabolic syndrome: a cross-sectional epidemiological, pan-India study,” International Journal of Endocrinology, vol. 2018, Article ID 2930251, 6 pages, 2018.

[59] B. H. R. Wolffsenbuttel, H. J. C. M. Wouters, S. N. Slagter et al., “Thyroid function and metabolic syndrome in the population-based Life lines cohort study,” BMC Endocrine Disorders, vol. 17, no. 65, pp. 1–11, 2017.